Current Investments
Tepha Inc.
Simon Williams, Lexington, MA, US
Tepha’s proprietary technology utilizes genetic engineering to produce bioabsorbable polymers, known as polyhydroxyalkanoates (PHAs). Potential products range from medical devices, such as surgical patches, sutures and ligaments to cardiovascular stents and drug delivery systems.
Tokai Pharmaceuticals
Seth Harrison; Cambridge, MA
Tokai develops best-in-class therapies for hormone-dependent growth disorders. The company's lead program is a proprietary small molecule Specific Androgen Receptor Modulator/Lyase Inhibitor (SARM/LI) for Castration Resistant Prostate Cancer (CRPC), a disease that kills around 30,000 men annually in the U.S.
Trellis Bioscience, Inc.
Stote Ellsworth, South San Francisco, CA, US
Trellis Bioscience is a private biotechnology company leveraging its proprietary CellSpot™ technology to deliver higher quality therapeutic monoclonal antibodies. The company has programs in infectious disease and oncology.